Effect of Pioglitazone on Mitochondrial Function in Muscle and Adipose Tissue in Humans (PIO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01165190
Recruitment Status : Unknown
Verified July 2010 by Arizona State University.
Recruitment status was:  Recruiting
First Posted : July 19, 2010
Last Update Posted : July 19, 2010
Takeda Pharmaceuticals North America, Inc.
Information provided by:
Arizona State University

Brief Summary:

Mitochondrial dysfunction in skeletal muscle results in decreased muscle fatty acid oxidation, leading to conversion of fatty acids into triglycerides and its accumulation inside the muscle tissue. Moreover, in adipose tissue mitochondrial dysfunction results in decreased fatty acid oxidation and triglyceride synthesis, leading to increased circulating fatty acid concentrations, which in turn also leads to lipid accumulation inside muscle tissue. Lipid accumulation inside muscle tissue interferes with the insulin signaling pathway and causes insulin resistance. Mitochondrial dysfunction in both tissues has therefore been proposed to play an important role in insulin resistance in humans.

Pioglitazone, a thiazolidinedione, is an FDA approved medication for the treatment of type 2 diabetes. It improves muscle insulin sensitivity at least in part by lowering intramuscular lipid concentrations but the mechanism by which this occurs is unclear. In the present study, we shall therefore test the hypothesis that pioglitazone improves mitochondrial function in muscle and adipose tissue in humans who are insulin resistant.

Condition or disease
Type II Diabetes Mellitus

Study Type : Observational
Estimated Enrollment : 20 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Effect of Pioglitazone on Mitochondrial Function in Muscle and Adipose Tissue in Humans
Study Start Date : May 2008

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Pioglitazone group

Biospecimen Retention:   Samples Without DNA
Blood, urine, and adipose tissue will be collected.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Both men and women, ages 18-65, any ethnicity.

Inclusion Criteria:

  1. Subjects must be able to communicate meaningfully with the investigator and must be legally competent to provide written informed consent.
  2. Subjects may be of either sex with age as described in each protocol. Female subjects must be non-lactating and will be eligible only if they have a negative pregnancy test throughout the study period.
  3. Subjects must range in age from 18-65.
  4. Subjects must have the following laboratory values:

    • 2-hour OGTT plasma glucose 140-250 mg/dl
    • Hematocrit ≥ 35 vol%
    • Serum creatinine ≤ 1.6 mg/dl
    • AST (SGOT) < 2.5 times upper limit of normal
    • ALT (SGPT) < 2.5 times upper limit of normal
    • PT, PTT within the normal range

Exclusion Criteria:

  1. Subjects must not be receiving any medications with known effects on glucose tolerance unless the subject has been on stable dose of such agents for the past three months before entry into the study. Subjects taking systemic glucocorticoids will be excluded. Subjects may be taking a stable dose of estrogens or other hormonal replacement therapy, if the subject has been on these agents for the prior three months.
  2. History of clinically significant heart disease, including ischemic heart disease (New York Heart Classification greater than grade II; more than non-specific ST-T wave changes on the EKG) and congestive heart failure
  3. History of peripheral vascular disease (history of claudication)
  4. History of pulmonary disease (dyspnea on exertion of one flight or less; abnormal breath sounds on auscultation).
  5. History of peripheral edema
  6. Uncontrolled hypertension with systolic BP>160 mmHg, diastolic BP>100 mmHg
  7. Resting heart rate >100 beats/min
  8. Autonomic neuropathy
  9. Heavy alcohol consumption (> 2 drinks/day)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01165190

Contact: Christian Meyer, MD (480) 965-2473

United States, Arizona
Clinical Research Unit Recruiting
550 East Orange Street, Arizona, United States, 85287
Contact: Christian Meyer, MD    (480) 965-2473   
Sponsors and Collaborators
Arizona State University
Takeda Pharmaceuticals North America, Inc.

Responsible Party: Christian Meyer, M.D., Arizona State University Identifier: NCT01165190     History of Changes
Other Study ID Numbers: 07-012A
First Posted: July 19, 2010    Key Record Dates
Last Update Posted: July 19, 2010
Last Verified: July 2010

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Hypoglycemic Agents
Physiological Effects of Drugs